

AbCellera inks $515m deal to build antibody facility in Canada
The co-investment with the Governments of Canada and British Columbia will fund construction of antibody-based facilities to bolster capabilities and infrastructure. The CA$701 million ($515 million) investment aims to strengthen Canada’s capabilities and infrastructure for drug development, p ...
MilliporeSigma will invest €35 million ($37 million) in biosafety testing at its Stirling and Glasgow sites in Scotland. MilliporeSigma – ...
The funding will support the launch of a CGT facility in Bristol, UK and cement the firm’s CDMO status, says eXmoor pharma. Cell and gene th ...
Quality control issues have landed UCB Pharma a Form 483 following an inspection of its facilities in Braine-l'Alleud, Belgium. UCB Pharma und ...
Sustainability initiatives are launching across the biopharmaceutical industry as companies begin to scrutinize their environmental impacts as pa ...